Since 2023, the number of A-share 100-yuan shares has declined. According to data from Oriental Wealth Choice, as of December 26**, the number of A-share 100-yuan shares was 80, and at the beginning of 2023, the number of A-share 100-yuan shares was 110, a decrease of nearly 30% compared with the beginning of the year. It is worth mentioning that in the latest list of 100 yuan stocks, nearly sixty percent of them are from the Science and Technology Innovation Board. In addition, compared with the beginning of the year, the team of 100 yuan stocks has changed greatly, and 53 ** have fallen behind, among them, *ST Zuojiang (300799), which is known as the "most expensive ST stock", has fallen the most obviously.
The number of 100-dollar stocks was reduced to 80.
According to the data of Oriental Wealth Choice, as of December 26, the number of 100 yuan stocks on the A** market was 80, a significant decrease compared with the beginning of the year.
According to the data, on January 1 this year, according to the statistics of the former form of resumption, the number of 100-yuan stocks on the A** market was 110, and since 2023, the number of 100-yuan stocks has decreased by 30, a decrease of about 27 from the beginning of the year27%γ
It is worth mentioning that the number of ** shares has decreased significantly. According to the data of Oriental Wealth Choice, under the form of pre-compounding, there were 3 ** shares of more than 500 yuan at the beginning of the year, and 10 shares of more than 300 yuan**, of which more than 500 yuan shares** include 3 shares of Kweichow Moutai, Hoymiles shares and Aimeike. However, as of December 26**, the share price of Hoymiles shares and Aimeike fell below 500 yuan shares, and only Kweichow Moutai had a share price of more than 500 yuan per share, and the latest stock price was 1670 yuan shares.
In addition, as of December 26, there are only 3 shares above 300 yuan, in addition to Kweichow Moutai, there are 2 shares of Huitai Medical and Jinshan Office, and the latest ** price is 37198 yuan shares, 3077 yuan shares. The latest stock prices of 14 shares, including Mindray Medical, Roborock, Yirui Technology, and Aimeike, are between 200 and 300 yuan shares, and the number of shares in this stock price range at the beginning of the year was 16.
A reporter from Beijing Business Daily noticed that among the top 10 stock prices at the beginning of the year, only the share price of Huitai Medical, the second largest stock in the new year, appeared during the year, and ninety percent of them appeared to varying degrees. Among them, Yuneng Technology fell the most, at 6937%, the company's latest ** price is 12334 yuan shares, the stock price was 402 before the beginning of the year67 yuan shares, once among the top five A-share stock prices.
Opt, Proya, Haohaishengke, etc. are currently only one step away from 100 yuan stocks. As of December 26**, the above 3 shares** were priced at 9973 yuan shares, 9913 yuan shares, 98$82 shares.
Nearly sixty percent are from the Science and Technology Innovation Board.
From the perspective of the sector, in the latest list of 100 yuan stocks, nearly sixty percent of the ** are from the Science and Technology Innovation Board.
According to the data of Oriental Wealth Choice, as of December 26, there were 47 stocks with a share price of more than 100 yuan on the Science and Technology Innovation Board, accounting for about 5875%γ
According to statistics, a total of 6 shares in the Science and Technology Innovation Board have entered the top 10 of the latest A-share stock price. Among them, the current A-share No.
Second, the third largest ** shares, Huitai Medical and Jinshan Office, are all from the Science and Technology Innovation Board. In addition, 4 shares of Roborock, Yirui Technology, Hoymiles and Baichu Electronics are also from the Science and Technology Innovation Board, and the latest stock prices are ranked fifth, sixth, eighth and tenth respectively.
Bai Wenxi, chief economist of IPG China, said in an interview with a reporter from Beijing Business Daily that the Science and Technology Innovation Board is an emerging market established by China to support the financing of scientific and technological innovation enterprises. In addition, the Science and Technology Innovation Board has attracted a large number of institutional investors and qualified investors, who have a high acceptance of emerging industries, helping the formation of ** stocks.
According to Yang Haiping, a researcher at the Research Institute of the University of Finance and Economics and general manager of the Research and Development Department of the Bank of Inner Mongolia, according to the development positioning, the Science and Technology Innovation Board has gathered high-growth enterprises that are in line with the national strategy, have key core technologies, have outstanding scientific and technological innovation capabilities, and mainly rely on core technologies to carry out production and operation. The current market environment has prompted investors to pay more attention to the high-quality science and technology innovation board with outstanding track value and growth value, which is the reason for the large number of ** stocks on the science and technology innovation board.
In addition, as of December 26, among the top 10 A-share stock prices, Aimeike and Mindray Medical are from the GEM, and 1 on the main board of the Shanghai Stock Exchange and 1 on the Beijing Stock Exchange, namely Kweichow Moutai and Jinbo Biotechnology.
Since the beginning of this year, there have been 6 newly listed ** stocks in the year, which are Anjiesi, Suochen Technology, Maolai Optics, Longxun Shares, Baili Tianheng, and Jinbo Biotechnology, among which, except for Jinbo Biotechnology, the rest are new stocks on the Science and Technology Innovation Board.
53 shares fell behind.
It is worth noting that compared with the beginning of the year, the members of 100 yuan shares have changed greatly, and a total of 53 shares have fallen out of the ranks of 100 yuan shares.
After the screening of Oriental Wealth Choice, a total of 53 shares were above 100 yuan in shares before the beginning of this year, and the latest ** price was below 100 yuan shares.
So far, a total of 20 of the above 53 stocks** have fallen by more than 50% during the year. Among them, the largest decline in stock price during the year was the "most expensive ST stock" *ST Zuojiang, which has attracted a lot of attention recently.
According to the data of Oriental Wealth Choice, at the beginning of this year, the stock price of *ST Zuojiang was 13036 yuan shares, the company's ** price on December 26 was 3104 yuan shares, down 7619%γAt the same time, *ST Zuojiang is also the lowest latest stock price among the above 53 shares**.
It is worth mentioning that on December 14, *ST Zuojiang was still a 100-yuan stock. Recently, *ST Zuojiang's share price has fallen sharply, and it just stopped falling on December 26, closing up 907%, the stock price rebounded above 30 yuan shares. Oriental Fortune shows that from December 13th to 25th, the cumulative decline in the *ST Zuojiang range was 8494%, falling for many consecutive trading days.
In response to company-related issues, a reporter from Beijing Business Daily called the office of the secretary of the board of directors of *ST Zuojiang for an interview, but no one answered from the other party.
In addition, Li Yuanheng and Haiyou New Materials also fell significantly during the year, of which Li Yuanheng's latest ** price was 3589 yuan shares, the latest ** price of Haiyou New Materials is 5835 yuan shares, Li Yuanheng and Haiyou New Materials fell respectively during the year. 48%γ
Bai Wenxi said that the situation of large changes in the seats of 100 yuan stocks is a natural embodiment of the survival of the fittest in the market, and the slowdown in performance growth and intensified market competition may lead to the adjustment of corporate stock prices. Investors need to pay attention to corporate fundamentals, grasp the market rhythm, and allocate assets reasonably. At the same time, the regulatory authorities should also strengthen the supervision of the market, maintain market order, and ensure the healthy and stable development of the capital market.
Beijing Business Daily reporter Ding Ning.